# Aortyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aortyx

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.aortyx.com
- Total disclosed funding: $16M
- Latest round: Series A (Jun 12, 2025)
- Investors on record: 5

## About

Based in Barcelona, Spain, Aortyx is a pioneer in developing innovative endovascular devices that target aortic diseases, leveraging advanced bioresorbable technology for tissue regeneration.Aortyx specializes in creating solutions for aortic diseases through cutting-edge endovascular devices. Founded in 2018 by Jordi Martorell and Noemí Palasí, the company has undergone significant development to establish its market presence. Aortyx, headquartered in Barcelona, Spain, has a current valuation of EUR 9.041 mn. Aortyx provides advanced endovascular devices aimed at treating aortic diseases, focusing on tissue regeneration through a bioresorbable platform. Their flagship product is a regenerative drug delivery system designed to improve patient outcomes, accommodating the specific biomechanical environment of the aorta. The company caters primarily to healthcare institutions, partnering with hospitals and specialized clinics across Europe and North America to ensure effective treatment for vascular conditions. In 2018, Aortyx reported no revenue, while in 2022, the company recorded an EBITDA loss of EUR 328,168.1. The company generates revenue through direct transactions with healthcare providers and medical institutions, focusing on establishing B2B partnerships for its advanced medical devices. In June 2025, Aortyx raised EUR 13.8 million in series A funding co-led by new investors Ship2B Ventures and Clave Capital, with participation from other new investors Nara Capital, European Innovation Council, and Center for Technological & Industrial Development. Individuals other unspecified investors also participated in the round. The company plans to utilize the June 2025 funding to achieve the milestone of initiating the first clinical trials involving patients. Aortyx is committed to meeting its development timelines to ensure the timely introduction of its new product offerings.

## Funding rounds

- Series A, Jun 12, 2025, $16M — Nara Capital, Clave Capital, European Innovation Council, Ship2B Ventures, Center for Technological & Industrial Development

## Investors

- Nara Capital (https://capitalatlas.ai/funds/nara-capital) — Series A
- Clave Capital — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A
- Ship2B Ventures (https://capitalatlas.ai/funds/ship2b-ventures) — Series A
- Center for Technological & Industrial Development (https://capitalatlas.ai/funds/center-for-technological-industrial-development) — Series A